# Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

> **NCT01926197** · PHASE3 · COMPLETED · sponsor: **Stanford University** · enrollment: 27 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5FU
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT01926197
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-14
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01926197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01926197, "Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01926197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*